SIGLEC1 and rheumatoid arthritis: DMARD naïve RA patients (21.83% ± 22.80, n = 6, p = 0.039) and DMARD responders (21.89% ± 26.31, n = 24, p = 0.014) have a significantly increased relative number of CD169+ classical monocytes, compared to healthy controls (9.426% ± 5.890, n = 19), although DMARD naïve patient number is relatively low.